{"id":320,"date":"2014-09-11T16:48:18","date_gmt":"2014-09-11T16:48:18","guid":{"rendered":"http:\/\/bcgfl.com\/site\/?p=320"},"modified":"2014-09-11T16:48:18","modified_gmt":"2014-09-11T16:48:18","slug":"center-for-medicare-medicaid-services-fact-sheet","status":"publish","type":"post","link":"http:\/\/bcgfl.com\/site\/?p=320","title":{"rendered":"Center for Medicare & Medicaid Services – Fact Sheet"},"content":{"rendered":"

The following is excerpted from the following website: http:\/\/www.cms.gov\/CCIIO\/Resources\/Fact-Sheets-and-FAQs\/aca_implementation_faqs18.html<\/a><\/p>\n

 <\/p>\n

Q1: On September 24, 2013, the USPSTF issued new recommendations with respect to breast cancer.<\/b>5<\/sup><\/b><\/a> What changes must plans make to comply with the new recommendations?<\/b><\/p>\n

The USPSTF recently revised its \u201cB\u201d recommendation regarding medications for risk reduction of primary breast cancer in women. The September 2013 recommendation now says:<\/p>\n

The USPSTF recommends that clinicians engage in shared, informed decisionmaking with women who are at increased risk for breast cancer about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen or raloxifene.<\/p>\n

Accordingly, for plan or policy years beginning one year after the date the recommendation or guideline is issued (in this case, plan or policy years beginning on or after September 24, 2014), non-grandfathered group health plans and non-grandfathered health insurance coverage offered in the individual or group market will be required to cover such medications for applicable women without cost sharing subject to reasonable medical management.
\n